` TBIO (Telesis Bio Inc) vs S&P 500 Comparison - Alpha Spread

TBIO
vs
S&P 500

Over the past 12 months, TBIO has underperformed S&P 500, delivering a return of -97% compared to the S&P 500's 10% growth.

Stocks Performance
TBIO vs S&P 500

Loading
TBIO
S&P 500
Add Stock

Performance Gap
TBIO vs S&P 500

Loading
TBIO
S&P 500
Difference
www.alphaspread.com

Performance By Year
TBIO vs S&P 500

Loading
TBIO
S&P 500
Add Stock

Competitors Performance
Telesis Bio Inc vs Peers

S&P 500
TBIO
0KHE
TMO
DHR
207940
Add Stock

Telesis Bio Inc
Glance View

Market Cap
177.3k USD
Industry
Life Sciences Tools & Services

Telesis Bio, Inc. engages in research and development of genomic tools for biomedical and industrial applications. The company is headquartered in San Diego, California and currently employs 212 full-time employees. The company went IPO on 2021-06-18. Its synthetic biology solution addresses bottlenecks across the multi-step process of building DNA and mRNA, as well as the limitations of existing solutions that prevent the building of DNA and mRNA at a useable scale. Its BioXp system is an end-to-end automated workstation. The firm's products include BioXp systems, including BioXp 3250 system, BioXp kits for generating a range of synthetic DNA and mRNA, and benchtop reagents that complement the automated synthetic biology workflow applications and workflow solutions. The company has launched eight BioXp kits, three benchtop reagent kits, and various other synthetic biology products, including 14 SARS-CoV-2 full-length genomes and RNA controls, as well as its Vmax X2 cells. The company has placed approximately 200 BioXp systems globally.

TBIO Intrinsic Value
Not Available
Back to Top